Becker's Healthcare July 24, 2025
The first postpartum depression drug zuranolone, sold under the brand name Zurzuvae, has shown mixed results since its release a year and a half ago, according to a July 22 report in The New York Times. Physicians are navigating the questions of why some women benefit and others do not. About 1 in 8 women experience postpartum depression symptoms, according to the CDC.
Here are five things to note:
- Clinical trials found that 60% of women with postpartum depression reported symptom improvement after completing the FDA-approved, 14-day oral medication course.
- Some women reported their symptoms “improved remarkably” as early as three days after starting the drug. Most antidepressant medications do not produce results until four to...
Today's Sponsors
Today's Sponsor